Camel Milk Exosomes Potentiate The Anticancer Effect of Doxorubicin on Multidrug-Resistant Human Leukemia Hl60 Cells in Vitro and in Vivo

Background: Multidrug resistance (MDR) is one of the strategies developed by cancer cells to inhibit anticancer potential majority chemotherapeutic agents and almost results in treatment failure. Objective: This study aimed evaluate therapeutic camel milk exosomes (CME) on multidrug-resistant human acute promyelocytic leukemia HL60 (HL60/RS) investigate whether this CME could potentiate effect Doxorubicin (DOX) decrease its side effects. Results: alone or combined with DOX significantly induced HL60/RS cell viability loss, apoptosis, cycle arrest at G0/G1 phase, downregulated MDR genes (Abcb1, Abcc1, Abcg2) as compared treated alone. Additionally, co-treated nude mice had lowest tumor volume, Abcb1, Abcg2, Bcl2 expression, highest Bax caspase3 expression xenografts. therapy also decreased adverse effects revealed liver damage enzymes lipid peroxide (MDA) increased hepatic antioxidant (SOD, CAT, GPx). Conclusion: sensitivity through, least part, reduction genes, induction arrest. Thus, may be used safe adjuvants during treatment. Keywords: Camel exosomes; Myeloid leukemia; HL60; Apoptosis;